The anaplastic lymphoma kinase (ALK) inhibitors market is set to reach from US$ 1,496.4 million in 2018 to 8,329.1 million by 2027, keen to demonstrate exuberant growth at a compounded annual growth rate (CAGR) of 21.2% during the forecast period from 2019 to 2027. Lung cancer is the second most common type of cancer in both men and women worldwide. Increased consumption of tobacco, an unhealthy lifestyle, and stress are the major risk factors responsible for the occurrence of lung cancer. A strong pipeline of second and third-generation ALK inhibitors is currently being studied in various stages of clinical trials and is being developed specifically for the treatment of non-small cell lung cancer (NSCLC).
Market Synopsis
Excellent pharmacodynamic and pharmacokinetic properties drive the market growth of first-generation ALK inhibitors.
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer occurring throughout the globe. The prognosis of NSCLC is difficult, and its initial screening is rather poor, which significantly increases the requirement for the development of targeted drug therapy for its treatment. The FDA has approved only 2 drugs specifically for the treatment of NSCLC.
In the present scenario, the first-generation ALK inhibitor Crizotinib is spearheading the molecule segment of the anaplastic lymphoma kinase inhibitor market. It is basically an aminopyridine and piperidine derivative that selectively inhibits receptor tyrosine kinase and the ALK fusion proteins during the treatment of NSCLC. It has the potency to inhibit tumor cell growth.
Alectinib hydrochloride is another first-line ALK inhibitor that effectively inhibits wild-type ALK point mutant variants and disrupts the tumor cell growth associated with advanced-stage NSCLC. Hence, excellent pharmacodynamic and pharmacokinetic properties together drive the market growth for first-generation ALK inhibitors.
Rising prevalence of lung cancer and an affordable reimbursement scenario together drive the market growth in the North American region.
North America, with a share of 36.2%, is currently leading the regional segment for anaplastic lymphoma kinase (ALK) inhibitors. According to the research findings of the American Society of Clinical Oncology (ASCO), in 2019, approximately 228,150 U.S. citizens have been reported to be suffering from lung cancer, with a high prevalence rate among African American people. Affordable reimbursement scenarios pertaining to the treatment of non-small cell lung cancer drive the market growth of ALK inhibitors in the North American region.
Europe is in second place with a 29.8% market share, primarily due to the huge prevalence rate of lung cancer in the European Union, which is 54 per 100,000 people, as brought forward by the 2018 statistical report of the European Commission. The supportive regulatory environment provided by the European Medical Agency expedites the clinical trials pertaining to second and third-generation anaplastic lymphoma kinase inhibitors for the treatment of non-small cell lung cancer (NSCLC).
Asia Pacific presently accounts for 15.5% of the market share and is keen to register outstanding growth during the forecast period on account of a significant rise in tobacco consumption, thereby promoting the proliferation of NSCLC and developing healthcare infrastructure.
Historical and Forecast Period
This research report presents the analysis of each segment from 2017 to 2027, considering 2018as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments is calculated for the forecast period from 2019 to 2027.
Report Scope by Segments
Biopharmaceutical companies actively seeking to create a strong foothold in the anaplastic lymphoma kinase inhibitor market are Betta Pharmaceuticals Co., Ltd., Crtierium, Inc., F. Hoffman-La Roche Ltd., Helsinn Therapeutics, Novartis AG, Oncoethix GmbH, Pfizer, Inc., Takeda Pharmaceutical Co., Ltd., Xcovery Holding Company, LLC, and Tesaro, Inc.
Key questions are answered in this report.
Which biopharmaceutical companies are engaged in the development of ALK inhibitors for the treatment of NSCLC?
What are the inorganic and organic market growth strategies adopted for the market assessment of the anaplastic lymphoma kinase inhibitor market?
What is the disease etiology associated with NSCLC?
Why are the first-line ALK inhibitors employed selectively for the treatment of NSCLC?
What is the prevalence rate of lung cancer in developing nations in the Asia-Pacific and Latin America regional segments?
Frequently Asked Question:
The market for Anaplastic Lymphoma Kinase Inhibitors Market is expected to reach USD$ 8,329.1 Mn in 2027.
The Anaplastic Lymphoma Kinase Inhibitors Market is expected to see significant CAGR growth over the coming years, at 21.2%.
The report is forecasted from 2019 -2027.
The base year of this report is 2018.
Betta Pharmaceuticals Co., Ltd., Crtierium, Inc., F. Hoffman-La Roche Ltd., Helsinn Therapeutics, Novartis AG,are some of the major players in the global market.
